This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tharimmune Prices $2.1 Million Private Placement of Common Shares, Warrants MT
Tharimmune, Inc. announced that it expects to receive $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group and other investors CI
Tharimmune, Inc. Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, Its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis CI
Tharimmune, Inc. Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis CI
Certain Warrants of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024. CI
Certain Options of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024. CI
Certain Common Stock of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024. CI
Tharimmune to Implement 1-for-15 Reverse Stock Split MT
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates CI
Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate CI
Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis CI
Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104 CI
Tharimmune Sees 'Positive' Data With TH104 for Pruritus in Chronic Liver Disease MT
Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients CI
Sector Update: Health Care Stocks Retreat in Late Afternoon MT
Top Midday Decliners MT
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell MT
Top Premarket Decliners MT
Tharimmune Prices $10 Million Public Share Offering MT
Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis CI
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Sector Update: Health Care Stocks Softer Friday Afternoon MT
Tharimmune to Implement 1-for-25 Reverse Stock Split MT
Chart Tharimmune, Inc.
More charts
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.82 USD
Average target price
75 USD
Spread / Average Target
+2,559.57%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. THAR Stock
  4. News Tharimmune, Inc.
  5. Tharimmune to Implement 1-for-15 Reverse Stock Split